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Figure	1.	Bar	charts	showing	regional	levels	of	Aβ	level	in	control	(black	bars)	and	AD	brains	(red	bars),	in	mid-frontal	cortex	(MF),	cingulate	cortex	(CC),	parahippocampal	cortex	(PH),	medial	parietal	cortex	(PC),	thalamus	(TH)	and	parietal	white	matter	(WM).	Bars	indicate	the	mean	and	SEM.	*P	<	0.05	**P	<	0.01	***P	<	0.001	****P	<	0.0001.	Lines	indicate	significant	differences	between	regions,	in	the	controls	(black	lines)	and	AD	groups	(red	lines);	the	thickness	of	the	line	indicates	the	significance	of	the	difference	between	the	two	regions,	ranging	from	P	<	0.01	to	P	<	0.0001.	
	
Figure	2.	Bar	chart	showing	regional	levels	of	clusterin	level	in	control	(black	bars)	and	AD	brains	(red	bars),	in	the	soluble	and	insoluble	brain	tissue	fractions.	Bars	indicate	the	mean	and	SEM.	*P	<	0.05	**P	<	0.01	***P	<	0.001.	Lines	indicate	significant	differences	between	regions,	in	the	controls	(black	lines)	and	AD	groups	(red	lines);	the	thickness	of	the	solid	lines	indicates	the	significance	of	the	difference	between	the	two	regions,	ranging	from	P	<	0.01	to	P	<	0.0001.	The	interrupted	horizontal	lines	indicate	differences	significant	at	the	P	<	0.5	level.	
	Figure	3.	Regional	association	between	clusterin	and	insoluble	Aβ42	levels.	The	concentration	of	clusterin	in		soluble	(A-B)	and	insoluble	(C-D)	brain	tissue	fractions		was	plotted	against	insoluble	Aβ42	level	in	each	region	in	controls	and	AD	cases.	The	solid	circles	and	thin	bars	indicate	the	mean	values	and	SEM	for	clusterin	(horizontal	bars)	and	Aβ42	(vertical	bars).	The	thick	solid	and	dotted	lines	indicate	the	best-fit	linear	regression	and	95%	confidence	intervals.	
	
Figure	4.	The	ratio	of	clusterin:insoluble	Aβ42	was	lowest	in	regions	with	a	predilection	for	Aβ42	deposition.	The	solid	circles	and	bars	indicate	the	mean	values	and	SEM.	
	
Figure	5.	Bar	charts	showing	clusterin	level	in	relation	to	APOE	genotype	(A-C)	and	severity	of	CAA.	Bars	indicate	the	mean	and	SEM.	*P	<	0.05	**P	<	0.01.	Clusterin	level	was	highest	in	APOE	ε4	homozygotes	in	MF	and	PC	and	increased	with	severity	of	CAA.	
	
Supplementary	Figure	1.	Stacked	bar	chart	illustrating	regional	differences	in	the	relative	contributions	of	soluble	and	insoluble	Aβ40	and	Aβ42	to	‘total’	Aβ	load	in	AD	and	control	brains	in	MF,	CC,	PH,	PC,	TH	and	WM.	
		
